Cargando…

A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration

Neurofilament light chain (Nf-L) is a well-known biomarker for axonal damage; however, the corresponding circulating Nf-L analyte in cerebrospinal fluid (CSF) is poorly characterized. We therefore isolated new monoclonal antibodies against synthetic peptides, and these monoclonals were characterized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Das, Shreyasee, Dewit, Nele, Jacobs, Dirk, Pijnenburg, Yolande A. L., In ‘t Veld, Sjors G. J. G., Coppens, Salomé, Quaglia, Milena, Hirtz, Christophe, Teunissen, Charlotte E., Vanmechelen, Eugeen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266977/ https://www.ncbi.nlm.nih.gov/pubmed/35806226 http://dx.doi.org/10.3390/ijms23137221

Ejemplares similares

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
por: Das, Shreyasee, et al.
Publicado: (2023)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
por: Meeter, Lieke H.H., et al.
Publicado: (2018)

Urine as matrix for analysis of neurofilament light chain is not suitable to distinguish frontotemporal dementia from psychiatric diseases
por: van Engelen, Marie-Paule E, et al.
Publicado: (2023)

Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges
por: Coppens, Salomé, et al.
Publicado: (2023)

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias
por: Bolsewig, Katharina, et al.
Publicado: (2022)

Clinical Value of Longitudinal Serum Neurofilament Light Chain in Prodromal Genetic Frontotemporal Dementia
por: Giannini, Lucia A.A., et al.
Publicado: (2023)

Neurofilament light chain: a biomarker for genetic frontotemporal dementia
por: Meeter, Lieke H., et al.
Publicado: (2016)

Potential sources of interference on Abeta immunoassays in biological samples
por: Vanderstichele, Hugo, et al.
Publicado: (2012)

The role of neurofilament light in genetic frontotemporal lobar degeneration
por: Zetterberg, Henrik, et al.
Publicado: (2022)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
por: Wesenhagen, Kirsten E. J., et al.
Publicado: (2022)

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
por: Vanderstichele, Hugo Marcel, et al.
Publicado: (2019)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
por: del Campo, Marta, et al.
Publicado: (2022)

Psychosis in behavioral variant frontotemporal dementia
por: Gossink, Flora T, et al.
Publicado: (2017)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies
por: Goossens, Joery, et al.
Publicado: (2015)

Late life bipolar disorder evolving into frontotemporal dementia mimic
por: Dols, Annemiek, et al.
Publicado: (2016)

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
por: Galasko, Douglas, et al.
Publicado: (2019)

Comparison of Chemiluminescence Enzyme Immunoassay (Cl-ELISA) with Colorimetric Enzyme Immunoassay (Co-ELISA) for Imidacloprid Detection in Vegetables
por: Zhai, Rongqi, et al.
Publicado: (2023)

Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia
por: Zanardini, Roberta, et al.
Publicado: (2022)

Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
por: Verde, Federico, et al.
Publicado: (2021)

Plasma Neurofilament Light Chain and Clinical Diagnosis in Frontotemporal Dementia Syndromes
por: Ooi, Suyi, et al.
Publicado: (2022)

Multicenter Analytical Validation of Aβ40 Immunoassays
por: van Waalwijk van Doorn, Linda J. C., et al.
Publicado: (2017)

A Practical Guide to Immunoassay Method Validation
por: Andreasson, Ulf, et al.
Publicado: (2015)

Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
por: Landqvist Waldö, Maria, et al.
Publicado: (2013)

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration
por: Rojas, Julio C., et al.
Publicado: (2021)

Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders
por: Vijverberg, Everard G.B., et al.
Publicado: (2017)

Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory
por: de Haan, Willem, et al.
Publicado: (2009)

YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer’s disease and frontotemporal lobar degeneration
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2022)

Bioinformatics tools and data resources for assay development of fluid protein biomarkers
por: Waury, Katharina, et al.
Publicado: (2022)

Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset
por: Fieldhouse, Jay L.P., et al.
Publicado: (2021)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
por: Rohrer, Jonathan D., et al.
Publicado: (2016)

Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration
por: Goossens, Joery, et al.
Publicado: (2018)

Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia
por: Spotorno, Nicola, et al.
Publicado: (2020)

Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias
por: Meda, Francisco, et al.
Publicado: (2023)

Schizophrenia as a mimic of behavioral variant frontotemporal dementia
por: Kerssens, Cora J., et al.
Publicado: (2016)

Electrochemical Impedance Immunoassay for ALS-Associated Neurofilament Protein: Matrix Effect on the Immunoplatform
por: Adil, Omair, et al.
Publicado: (2023)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n4ntvanij8pobgfvv6k87bhou2